High‐dose cyclophosphamide and adriamycin with DTIC maintenance for metastatic soft tissue sarcomas
- 1 August 1983
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 23 (4) , 282-284
- https://doi.org/10.1002/jso.2930230413
Abstract
Intensive chemotherapy with high-dose cyclophosphamide and adriamycin with DTIC [5(3,3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide] maintenance was given to 12 patients with metastatic soft tissue sarcomas. A partial response rate of 25% was seen; the same results have been achieved with single-agent therapy. Because of substantial toxicity without improved efficacy, the trial of high dose therapy was halted.This publication has 9 references indexed in Scilit:
- Chemotherapy of SarcomataJournal of the Royal Society of Medicine, 1982
- Combination chemotherapy (CYVADIC) in metastatic soft tissue sarcomasEuropean Journal of Cancer and Clinical Oncology, 1982
- Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)Cancer, 1980
- Dose response evaluation of adriamycin in human neoplasiaCancer, 1977
- A Clinical Trial Adriamycin (NSC 123127) in Advanced SarcomasOncology, 1976
- Chemotherapy of sarcomasCancer, 1975
- Adriamycin: A new effective agent in the therapy of disseminated sarcomasMedical and Pediatric Oncology, 1975
- Phase II evaluation of adriamycin in human neoplasiaCancer, 1973
- Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamideCancer, 1972